Clinical trials: Endometrioid Carcinoma Ovary
Epithelial Ovarian Cancer, Primary Peritoneal
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer
- Trial name
- NCT06690775
- Testing
- TORL-1-23, Pegfilgrastim (drug)
- Where
- 66 sites in United States, Australia and 10 more
- Volunteers
- 230 people
- Sponsor
- TORL Biotherapeutics, LLC
Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ovarian cancer that has come back (recurrent).
- Conditions
- Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT05231122
- Testing
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Roswell Park Cancer Institute
Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer
This phase II trial studies how well tazemetostat works in treating patients with ovarian or endometrial cancer that has come back (recurrent).
- Conditions
- Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma
- Trial name
- NCT03348631
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Tazemetostat
- Where
- 581 sites in United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
This randomized phase III trial studies carboplatin, paclitaxel, and bevacizumab to see how well they work compared to carboplatin, paclitaxel, and placebo in treating patients with stage III or stage IV ovarian epithelial…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma
- Trial name
- NCT00262847
- Testing
- Bevacizumab, Carboplatin, Laboratory Biomarker Analysis
- Where
- 632 sites in United States, Canada and 2 more
- Volunteers
- 1,873 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer
Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass
RATIONALE: Finding specific proteins in the blood may help doctors tell whether a patient has ovarian cancer. PURPOSE: This clinical trial is studying how well proteomic profiling works in diagnosing ovarian cancer in patients…
- Trial name
- NCT00238342
- Testing
- proteomic profiling, surface-enhanced laser desorption/ionization-time of flight mass spectrometry, biopsy
- Where
- 107 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Gynecologic Oncology Group
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma
Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy
This phase II trial compares the effect of sacituzumab govitecan and bevacizumab to standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) in patients with ovarian cancer that has come back after an initial…
- Conditions
- Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma
- Trial name
- NCT07504588
- Testing
- Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection
- Where
- 13 sites in United States
- Volunteers
- 87 people
- Sponsor
- National Cancer Institute (NCI)
Serous Ovarian Tumor, Endometrioid Carcinoma Ovary
Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study
A pilot study to evaluate the feasibility of a NGS-based tumour BRCA1/2 mutation testing pathway initiated in the oncology clinic for patients with HGSEC, either at primary diagnosis or first relapse, whereby only patients with a…
- Conditions
- Serous Ovarian Tumor, Endometrioid Carcinoma Ovary, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT06274541
- Testing
- Somatic and Germline BRCA1/2 Testing
- Where
- 5 sites in Ireland
- Volunteers
- 200 people
- Sponsor
- Cancer Trials Ireland
Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
This phase I trial studies the side effects and best dose of peposertib when given together with pegylated liposomal doxorubicin hydrochloride in treating patients with high or low grade ovarian cancer that has come back after a…
- Conditions
- Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma
- Trial name
- NCT04092270
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 11 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of vaccine therapy with or without sargramostim in treating patients who have advanced or metastatic cancer. Vaccines may make the body build an immune response to kill tumor cells.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder, Adenocarcinoma of the Pancreas, Adenocarcinoma of the Rectum
- Trial name
- NCT00028496
- Testing
- recombinant fowlpox-CEA(6D)/TRICOM vaccine, sargramostim, recombinant fowlpox GM-CSF vaccine adjuvant
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Ovary Cancer, Fallopian Tube Cancer
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
This is a phase 2 study to test the effectiveness (anti-tumor activity) of the combination of the study drugs, Senaparib and Temozolomide, in patients with clear cell or endometrioid ovarian cancers that have ARID1A pathologic…
- Conditions
- Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT06617923
- Testing
- Senaparib, Temozolomide
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cervical Cancer, Fallopian Tube Cancer
Immunotoxin Therapy in Treating Patients With Advanced Cancer
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be an effective treatment for advanced cancer.
- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00006981
- Testing
- SS1(dsFv)-PE38 immunotoxin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
This phase II trial studies the possible benefits of treatment with different combinations of the drugs durvalumab, olaparib and cediranib vs.
- Conditions
- Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma
- Trial name
- NCT04739800
- Testing
- Biospecimen Collection, Cediranib Maleate, Computed Tomography
- Where
- 391 sites in United States, Puerto Rico
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells.
- Trial name
- NCT00003322
- Testing
- cisplatin, paclitaxel, quality-of-life assessment
- Where
- 67 sites in United States, Canada
- Volunteers
- 384 people
- Sponsor
- Gynecologic Oncology Group
Fatigue, Malignant Ovarian Mixed Epithelial Tumor
Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy
This randomized phase III trial studies how well acetyl-L-carnitine hydrochloride works compared to a placebo in preventing peripheral neuropathy in patients with recurrent ovarian epithelial cancer, primary peritoneal cancer, or…
- Conditions
- Fatigue, Malignant Ovarian Mixed Epithelial Tumor, Neuropathy, Neurotoxicity Syndrome
- Trial name
- NCT01492920
- Testing
- Acetyl-L-Carnitine Hydrochloride, Questionnaire Administration, Quality-of-Life Assessment
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer
Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer
The goal of this clinical study is to learn more about the safety, tolerability, and preliminary effectiveness of TUB-040 when given in combination with standard ovarian cancer treatments in participants with high-grade…
- Trial name
- OC (NCT07736937)
- Testing
- TUB-040 + Carbo + BEV
- Where
- 8 sites in United States, Belgium and 1 more
- Volunteers
- 72 people
- Sponsor
- Gilead Sciences
Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Neoplasm
Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase II trial studies how well physical activity monitored by Fitbit Charge 2 works in improving quality of life in participants with ovarian, primary peritoneal, or fallopian tube cancer that has come back.
- Conditions
- Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Neoplasm, Fallopian Tube Serous Neoplasm, Ovarian Clear Cell Tumor
- Trial name
- NCT03685695
- Testing
- Laboratory Biomarker Analysis, Monitoring Device, Physical Activity
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
Low Grade Ovarian Serous Adenocarcinoma, Endometrial Cancer
Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial
This is a phase 2, interventional treatment trial evaluating imlunestrant, abemaciclib, and selinexor in two separate patient cohorts: low grade serous ovarian cancer and endometrioid endometrial cancer.
- Trial name
- SIERRA (NCT07832227)
- Testing
- Imlunestrant, Abemaciclib, Selinexor
- Volunteers
- 60 people
- Sponsor
- Dana-Farber Cancer Institute
Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
The purpose of this study is to evaluate the efficacy of addition of letrozole to the standard maintenance therapy in subjects following a primary diagnosis of Estrogen-receptor (ER) positive high and low grade epithelial ovarian…
- Conditions
- Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma (HGSOC)
- Trial name
- MATAO (NCT04111978)
- Testing
- Letrozole 2.5mg
- Where
- 53 sites in Austria, Germany and 1 more
- Volunteers
- 540 people
- Sponsor
- Swiss GO Trial Group
Malignant Ovarian Mixed Epithelial Tumor, Ovarian Clear Cell Cystadenocarcinoma
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer
Phase II trial to study the effectiveness of combination chemotherapy and peripheral stem cell transplantation in treating patients who have undergone surgery for stage III ovarian cancer.
- Conditions
- Malignant Ovarian Mixed Epithelial Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma
- Trial name
- NCT00004221
- Testing
- Carboplatin, Cyclophosphamide, Filgrastim
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer
Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003644
- Testing
- carboplatin, paclitaxel
- Where
- 151 sites in United States, Japan
- Volunteers
- 571 people
- Sponsor
- Gynecologic Oncology Group